Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

11 nov. 2020 07h00 HE | Source: Achilles Therapeutics

Achilles Therapeutics Announces Grant of European Patent Covering Use of Selectively Expanded T cells Targeting Clonal Neoantigens for the Treatment of Cancer

Achilles Therapeutics Announces Grant of European Patent Covering Use of Selectively Expanded T cells Targeting Clonal Neoantigens for the Treatment of Cancer - Related patent recently granted and...
07 avr. 2020 07h00 HE | Source: Achilles Therapeutics

Achilles Therapeutics appoints Carsten Boess to the Board of Directors

Achilles Therapeutics appoints Carsten Boess to the Board of Directors Stevenage, UK 7 April, 2020 – Achilles Therapeutics (“Achilles”), a clinical-stage oncology company developing personalised cell...
13 févr. 2019 07h00 HE | Source: Achilles Therapeutics

Achilles Therapeutics receives CTA Approval for Phase I/II Study in Metastatic or Recurrent Melanoma

Achilles Therapeutics receives CTA Approval for Phase I/II Study in Metastatic or Recurrent Melanoma Second CTA approval in 2019 – the first was for a NSCLC study Stevenage, UK 13 February...
13 févr. 2019 03h00 HE | Source: Achilles Therapeutics

Achilles Therapeutics receives CTA Approval for Phase I/II Study in Metastatic or Recurrent Melanoma

Achilles Therapeutics receives CTA Approval for Phase I/II Study in Metastatic or Recurrent Melanoma Second CTA approval in 2019 – the first was for a NSCLC study Stevenage, UK 13 February...